The regulatory body that licenses drugs for use in the European Union is devising a policy that will require the publication of some clinical trial data.
The regulatory body that licenses drugs for use in the European Union is devising a policy that will require the publication of some clinical trial data.
The total number of new drugs approved this year ties last year for the highest since 2004, suggesting that the pharmaceutical industry is recovering.
The US Food and Drug Administration is taking steps to get new devices on the market sooner—and antibiotics may be next.
Pharmaceutical and biotech companies ask the US Food and Drug Administration to ensure the independence of a third-party audit of its new drug program.
Page 1 of 1